1 / 23

Dr Andrew Rose MCRN Deputy Assistant Director

Driving Research Collaboration through NIHR Clinical Research Network: Focus on NIHR Medicines for Children Research Network. Dr Andrew Rose MCRN Deputy Assistant Director. NIHR Research Infrastructure. Invention. Evaluation. Adoption. Early-phase clinical research .

rupali
Download Presentation

Dr Andrew Rose MCRN Deputy Assistant Director

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Driving Research Collaboration through NIHR Clinical Research Network: Focus on NIHR Medicines for Children Research Network Dr Andrew Rose MCRN Deputy Assistant Director

  2. NIHR Research Infrastructure Invention Evaluation Adoption Early-phase clinical research Late-phase clinical research NIHR Biomedical Research Centres NIHR Biomedical Research Units NIHR Clinical Research Facilities Experimental Cancer Medicine Centres NIHR Health Technology Cooperatives NIHR Diagnostic Evidence Cooperatives NIHR Clinical Research Network NIHR CLAHRCs > £0.5 billion p.a. investment in relevant infrastructure to support clinical research at all points in the development pipeline Ravi Chana/Oliver Rausch (NOCRI)

  3. EU Regulation “Better medicines for children” • Became law in across EU on 26 January 2007 • Incentives and requirements for industry to undertake paediatric studies • Paediatric Committee • Based in European Medicines Agency • Paediatric Investigation Plan (PIP) • Development agreed with Paediatric Committee • Coordinated European Paediatric Trials Network

  4. MCRN’s Vision To improve children’s health and alleviate suffering through the provision of better and safer medicines • AIMS • The best infrastructure in the world to support studies which address the safety and efficacy of medicines for children. • An excellent base for clinical research for children which is an attractive resource for the global pharmaceutical industry. • To ensure that world-leading research addresses the needs of children.

  5. NIHR Medicines for Children Research Network • Large network supporting randomized and other studies of medicines for children in NHS sites • Work closely with Clinical Research Facilities (CRFs) etc • Supporting: • All phases • All therapy areas (except oncology) • Studies supported by MCRN • Industry-sponsored/funded • Publicly-sponsored, including • Investigator-initiated (industry supported) Research (IIR) • Publicly-funded industry and academic/NHS consortia

  6. Clinical Studies Groups (CSGs) 1. Allergy, Infection and Immunity (BPAIIG) Prof Saul Faust 2. Anaesthesia, Intensive Care and Cardiology Dr Mark Peters 3. Cleft and Craniofacial Anomalies Ms Rona Slater (Craniofacial Society of GB & I/The Healing Foundation) 4. Diabetes and Endocrinology (BSPED) Prof Timothy Barrett 5. Gastroenterology, Hepatology & Nutrition (BSPGHAN) Prof Stephen Allen 6. General Paediatrics (including Dermatology) (BAGP) Dr Alastair Sutcliffe 7. Inherited Metabolic Disorders Dr Chris Hendriksz (UK LSD Patient Collaborative Group) 8. Methodology Prof Ruth Gilbert 9. Neonatal (Action Medical Research) Dr Mark Turner 10. Nephrology (BAPN) Dr Richard Coward 11. Neurosciences Prof Helen Cross 12. Pain and Palliative Care (Louis DundasDev’ Fund) Dr Richard Howard 13. Pharmacy and Pharmacology Prof James McElnay 14. Respiratory and Cystic Fibrosis Dr Paul Seddon 15. Rheumatology (Arthritis Research UK) Prof Michael Beresford

  7. Local Research Networks (LRNs) and Areas LRN/Area staff support the conduct of paediatric research in the NHS and work in accordance with Good Clinical Practice (GCP) • Director • Manager • Research Nurses • Pharmacists • Data entry staff • Administration

  8. Growth of Portfolio

  9. Recruitment to studies Number of participants recruited

  10. Recruitment totarget (2012/13)

  11. Support for industry-sponsored and funded studies • Dedicated MCRN Industry Staff • Facilitate close working with companies and contract research organisations (CROs) • Interacted with close to 200 companies interested in children’s research • Detailed knowledge of/access to expertise • EU Paediatric Regulation (PIPs) • Study and programme design (inc pharmacy) • Implementation (feasibility, set-up, delivery) • Consumer matters (patient information etc) industry@mcrn.org.uk

  12. NIHR CRN Feasibility Services • Early Feedback • A rapid assessment of feasibility (10 days) by clinical specialists: • Current UK practice, prevalence of the relevant patient population • Network knowledge of competing studies etc. • Site Intelligence • Sites selected - process ensures that proposed recruitment targets are realistic (15 days) • Complements existing feasibility data • In parallel with other processes (study added to portfolio) • Site Identification • Identification of new sites (15 days) supportmystudy@nihr.ac.uk

  13. Growth of Industry Portfolio update

  14. Industry-sponsored and funded case study 1 • Systemic Juvenile Idiopathic Arthritis • Sponsored by F. Hoffmann-La Roche Ltd (Roche) • Tocilizumab in children aged 2 to 17 • Interactions between Rheumatology CSG and company • Despite significant challenges, the MCRN recruited on time and to target • Product now • Licensed for use in this setting and • Approved by National Institute for Health and Clinical Excellence (NICE) • Programme of related research with tocilizumab

  15. Industry-sponsored and funded case study 2 • Study to evaluate an antibody for the treatment of neonatal sepsis (Biosynexus) • 93 international sites (8 UK) • MCRN staff/resources supported: • Site identification (CRO found challenging) • Ethics approval • Site setup (costing/approvals/logistics) • Recruitment • Success in this and other neonatal studies have helped to attract other studies

  16. Licensed Products • Prevenar 13 vaccine/Pneumococcal disease • Cozaar/Proteinuria • Tocilizumab/systemic juvenile idiopathic arthritis (sJIA) • Xalatan (Latanoprost)/Glaucoma • Menveo vaccine/Meningococcal disease • Kalydeco (Ivacaftor)/Cystic fibrosis (G551D) • More in the pipeline... • Others no paediatric indication, but info added to SPC

  17. Investigator-initiated (industry supported) Research (IIR) • Publicly (NHS/Uni)-sponsored and led, with industry support: • Academic investigator develops protocol and approaches industry for: • Funding, drug, placebo, device and/or other support • Uni/NHS act as sponsor • Industry benefits • To support “research that advances medical and scientific knowledge about our products and that generates promising medical interventions” Pfizer.com • Retain product IP • Academic benefits • Access to products, funding etc to conduct research for the benefit of patients

  18. Investigator Studies Operations Group (ISOG) • UK Pharma Industry Group (with NIHR representation) • Discusses challenges with investigator-initiated studies • Working to standardise IIR contracts • Meets several times per year • Investigator Initiated-Sponsored Research Association (IISRA)

  19. IIR case study • SYCAMORE • RCT of Adalimumab in combination with Methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis • Clinical effectiveness, safety and cost effectiveness • CI - Dr Athimalaipet Ramanan • Sponsor - University Hospitals Bristol NHS Foundation Trust • Funders • NIHR Health Technology Assessment • Arthritis Research UK • Active and placebo provided by Abbvie (Abbott)

  20. Industry and academic/NHS consortia studies • Publicly funded: • EU FP7, MRC, NIHR Invention for Innovation (i4i) etc • Industry or public (NHS/University) sponsorship • Collaborative development of protocols/programmes • Industry benefits • Obtain funding, develop academic links, develop company expertise, IP and products, commercialisation opportunities • Academic/NHS benefits • Obtain funding, develop industry links, develop Uni/NHS team expertise, helps get products to patients, financial benefits (royalties/IP)

  21. Industry and academic consortia case study • Stratified medicine • Duchenne muscular dystrophy (DMD) • Collaboration including experts from London, Newcastle and Serepta Therapeutics (formerly AVI) • Study team (with support of NIHR infrastructure) designed and validated antisense oligonucleotides (“molecular patches”) for DMD gene • MCRN/CRF and other NIHR resources supported clinical study • Sponsor - AVI BioPharma • Funders - MRC and AVI BioPharma • Encouraging early results

  22. Children’s Research Industry Group (CRIG) • Direct MCRN links with industry previously not formalised • Established CRIG, for MCRN/wider NIHR to: • Improve collaboration with industry • Improve the support that we offer industry • Obtain support and advice on industry matters • Provide a forum for the discussion of children’s research issues of relevance to industry • Membership • Pharma • CRO • Med tech • Meetings 10 May 2013 and 23 September 2013 • Next early 2014

  23. industry@mcrn.org.uk www.mcrn.org.uk

More Related